Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT)....
Deciphera Pharmaceuticals has?posted?data from a phase 1 trial of its small molecule switch control inhibitor of CSF1R, DCC-3014. The early-phase data have emboldened Deciphera to expand the trial to include patients with....